Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADiTx Therapeutics

2.31
-0.1950-7.80%
Volume:277.09K
Turnover:632.07K
Market Cap:2.67M
PE:0.00
High:2.41
Open:2.41
Low:2.19
Close:2.50
Loading ...

Aditxt Inc Withdraws April 14 Release That Said Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

THOMSON REUTERS
·
18 Apr

Aditxt Inc Withdraws April 14 Release and Says No Replacement Release Will Be Issued

THOMSON REUTERS
·
18 Apr

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

Business Wire
·
17 Apr

Aditxt Subsidiary Pearsanta Receives Irb Approval To Initiate Clinical Study Of Blood-Based Diagnostic For Endometriosis With Patient Enrollment Planned To Begin In May 2025

Reuters
·
16 Apr

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Business Wire
·
16 Apr

BRIEF-Aditxt Subsidiary Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies To Support FDA And European Regulatory Submissions For Type 1 Diabetes, Psoriasis, And Stiff Person Syndrome Human Trials

Reuters
·
14 Apr

Aditxt Subsidiary Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

THOMSON REUTERS
·
14 Apr

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Business Wire
·
14 Apr

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Business Wire
·
11 Apr

Aditxt Inc - Enters Securities Purchase Agreement With Evofem Biosciences - SEC Filing

THOMSON REUTERS
·
10 Apr

BRIEF-Aditxt Regains Compliance With Nasdaq Listing Requirements

Reuters
·
09 Apr

Aditxt, Inc. (Nasdaq: Adtx) Regains Compliance With Nasdaq Listing Requirements

THOMSON REUTERS
·
09 Apr

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Business Wire
·
09 Apr

BRIEF-Appili President And CEO, Don Cilla To Join Aditxt CEO, Amro Albanna For Aditxt Weekly Update On April 4, 2025

Reuters
·
02 Apr

Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

THOMSON REUTERS
·
02 Apr

Appili President and CEO, Don Cilla Will Join Aditxt Co-Founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

THOMSON REUTERS
·
02 Apr

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based Case Platform and Its Potential for Early Cancer Detection

THOMSON REUTERS
·
28 Mar

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Business Wire
·
28 Mar

Evofem Reports Fourth Consecutive Year of Net Sales Growth

THOMSON REUTERS
·
24 Mar

ADiTx Therapeutics trading resumes

TIPRANKS
·
19 Mar